文献速递泌尿生殖与妇科肿瘤放疗

前列腺床加速大分割放疗的前瞻性1/2期研究5年结局

5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed.
PubMed 文献 · Pract Radiat Oncol · 2019-05-16

这项单中心前瞻性1/2期研究纳入30例根治性前列腺切除术后患者,给予前列腺床51 Gy/17次的大分割加速放疗;中位随访6.4年,无3/4级毒性,5年生化失败累积发生率分别为31%(nadir+0.2)和18%(nadir+2.0),提示该方案疗效良好且晚期毒性不显著。

要点

  • 30例术后患者接受51 Gy/17次前列腺床放疗,中位随访6.4年无3/4级毒性。
  • 5年生化失败累积发生率31%(nadir+0.2)与18%(nadir+2.0)。
  • 4年PSA≥0.4可预测后续雄激素剥夺治疗使用(P < .0001)。

核心结论

  • 大分割术后前列腺床放疗在本1/2期研究中显示出良好临床疗效且无显著晚期毒性,值得开展3期研究。

研究设计与样本

  • 单中心前瞻性1/2期研究,2008至2011年纳入30例根治性前列腺切除术后适合术后放疗的患者,处方剂量51 Gy/17次至前列腺床。

主要发现

  • 中位随访6.4年,无患者发生CTCAE 3/4级毒性,11例(37%)出现2级泌尿生殖毒性,2例(7%)出现2级胃肠道毒性。
  • 基线至放疗后5年,EPIC泌尿域平均分从80%(标准差18%)变为82%(17%),肠道域平均分从93%(13%)变为93%(15%)。
  • 分别有1例(4%)泌尿域和1例(4%)肠道域达到最小临床重要变化。
  • 5年生化失败累积发生率为31%(nadir+0.2)和18%(nadir+2.0),5年激素治疗使用累积发生率为14%。
  • 4年PSA≥0.4预测后续雄激素剥夺治疗使用(Nelson-Aalen累积发生率1.45;P < .0001),接受激素治疗者4年PSA均>0.4。

关键数值与推荐

  • 处方剂量为51 Gy分17次照射前列腺床。
  • 毒性评估采用NCI CTCAE 3.0版,生活质量采用EPIC问卷。
  • 生化失败定义包括nadir+0.2和nadir+2.0,5年累积发生率分别为31%和18%。

临床怎么用

  • 对于根治性前列腺切除术后适合术后放疗的患者,可考虑51 Gy/17次的大分割加速前列腺床放疗方案。
  • 治疗后需监测PSA,4年PSA≥0.4提示后续可能需要雄激素剥夺治疗。

局限性

  • 本研究为单中心1/2期研究,样本量仅30例,随访时间有限,结论需3期研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the 5-year outcomes from a single institution, prospective, phase 1/2 study on hypofractionated, accelerated radiation therapy to the prostate bed after radical prostatectomy. METHODS AND MATERIALS: Patients enrolled in this study were all eligible for postoperative radiation therapy and received a prescribed dose of 51 Gy in 17 fractions to the prostate bed. On follow-up, gastrointestinal (GI) and genitourinary (GU) toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0; prostate-specific antigen (PSA) was evaluated and quality of life was assessed using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. RESULTS: A total of 30 patients were enrolled between 2008 and 2011. Median age was 65 (52-75) years. Median pretreatment PSA was 0.12 ng/mL (0.01-1.42). Twenty-six (93%) patients had Gleason ≤7 disease, 13 (43%) had pT3 disease, and 20 (67%) had positive margins. Twenty-six patients (87%) underwent radiation therapy as salvage treatment. After a median follow-up of 6.4 (2.1-8.1) years, no patient experienced Common Terminology Criteria for Adverse Events grade 3/4 toxicity. Eleven patients (37%) had grade 2 genitourinary and 2 (7%) had grade 2 gastrointestinal toxicity. At baseline and 5 years after radiation therapy, mean EPIC urinary domain score was 80% (standard deviation, 18%) and 82% (17%). Mean EPIC bowel domain score was 93% (13%) and 93% (15%). One patient (4%) had a minimally clinically important change in urinary domain score and 1 patient (4%) had a minimally clinically important change in bowel domain score. Nelson-Aalen estimated cumulative incidence of biochemical failure was 31% (nadir +0.2) and 18% (nadir +2.0) at 5 years. Four-year PSA ≥0.4 was predictive of subsequent androgen deprivation therapy use (Nelson-Aalen cumulative incidence: 1.45; P < .0001). Five patients (17%) received hormonal therapy for biochemical failure. Nelson-Aalen estimated cumulative incidence of hormone therapy use was 14% at 5 years. All patients who received hormone therapy had PSA >0.4 at 4 years. CONCLUSIONS: In this phase 1/2 study, hypofractionated postoperative radiation therapy seems to have good clinical efficacy without significant late toxicity. Phase 3 studies are warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Martell K, Cheung P, Morton G, et al. 5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed. Pract Radiat Oncol. 2019. PMID: 31103715. doi:10.1016/j.prro.2019.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。